ACM
RVNC

Aquatic Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Aquatic Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,600
Closed -$172K – 1731
2023
Q4 		$172K Buy
+19,600
New +$161K ﹤0.01% 889
2023
Q3 		– Sell
-23,100
Closed -$585K – 1733
2023
Q2 		$585K Buy
+23,100
New +$720K 0.03% 418
2022
Q4 		– Sell
-3,300
Closed -$89K – 1901
2022
Q3 		$89K Buy
+3,300
New +$66.9K 0.01% 788

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aquatic Capital Management's RVNC Position: Q1 2024 in Review

Aquatic Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 19,600 shares — an estimated $172K sold.

Aquatic Capital Management first reported a position in RVNC in Q3 2022 and held it in 3 quarters. The position peaked at $585K in Q2 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Aquatic Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Aquatic Capital Management sold 19,600 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $172K.
  • Aquatic Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 3 quarters.
  • Aquatic Capital Management's Revance Therapeutics, Inc. position peaked at $585K in Q2 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Aquatic Capital Management's 13F filing for Q1 2024, filed 15 May 2024.